Cytek Biosciences, Inc. (CTKB)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Cytek Biosciences, Inc. reported revenue of $201.49M, up 0.5% from the prior year. The company ran a net loss, with a net margin of -33.0% and a gross margin of 51.8%. It held $461.54M in total assets against $119.80M in total liabilities.
Key ratios (FY2025)
51.8%
Gross margin
-20.0%
Operating margin
-33.0%
Net margin
-19.5%
Return on equity
+0.5%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $201.49M | $200.45M | $193.01M | $164.04M | $127.95M | $92.84M | — |
| Cost of Revenue | $97.03M | $89.35M | $83.59M | $63.06M | $48.81M | $41.13M | — |
| Gross Profit | $104.46M | $111.11M | $109.43M | $100.97M | $79.14M | $51.71M | — |
| Operating Income | -$40.38M | -$20.52M | -$27.84M | -$1.80M | $9.16M | $13.66M | — |
| Net Income | -$66.54M | -$6.02M | -$12.15M | $2.48M | $3.03M | $19.41M | — |
| EPS (Diluted) | — | — | $-0.09 | $0.02 | $0.00 | $0.10 | — |
| Total Assets | $461.54M | $499.50M | $494.46M | $519.48M | $463.31M | $219.98M | — |
| Total Liabilities | $119.80M | $103.76M | $101.39M | $93.93M | $57.92M | $41.69M | — |
| Shareholders' Equity | $341.74M | $395.74M | $393.06M | $425.55M | $405.38M | -$16.03M | $41.70M |
| Cash & Equivalents | $90.85M | $98.72M | $167.30M | $296.60M | $364.62M | $165.23M | — |
| Operating Cash Flow | -$4.69M | $25.38M | $5.28M | -$12.23M | $4.63M | $15.16M | — |
| Capital Expenditures | $4.08M | $3.52M | $4.65M | $9.75M | $4.36M | $1.55M | — |
| Shares Outstanding | 128.55M | 129.21M | 130.71M | 135.37M | 133.75M | 31.24M | — |